901TiP - Phase Ib/II study to evaluate the efficacy and tolerability of PM01183 (lurbinectedin) in combination with olaparib in patients with advanced solid...

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Gynaecological Malignancies
Presenter Andrés Poveda
Citation Annals of Oncology (2016) 27 (6): 296-312. 10.1093/annonc/mdw374
Authors A.M. Poveda1, A. Oaknin2, I. Romero1, A. Guerrero3, L. Fariñas Madrid4, A. Soto5, C. Peris6, J.A. Lopez Guerrero7
  • 1Oncogyn Department, Fundación Instituto Valenciano de Oncología, 46009 - Valencia/ES
  • 2Na, Vall d`Hebron University Hospital Institut d'Oncologia, 08035 - Barcelona/ES
  • 3Medical Oncology, Fundación Instituto Valenciano de Oncología, 46008 - Valencia/ES
  • 4Medical Oncology, Vall d`Hebron University Hospital Institut d'Oncologia, 08035 - Barcelona/ES
  • 5Clinical Research, PhamaMar, 28770 - Madrid/ES
  • 6Data Center, Fundación Instituto Valenciano de Oncología, 46009 - Valencia/ES
  • 7Laboratory Of Molecular Biology, Fundación Instituto Valenciano de Oncología, 46009 - Valencia/ES



PM01183 is a new anticancer drug that exerts antitumor activity through inhibition of trans-activated transcription and modulation of tumor microenvironment. Recently a significant activity in platinum-resistant ovarian cancer patients in terms of Response Rates (RR), has been reported (Poveda A et al. ASCO 2014.abstr #5505). PM01183 is currently being studied in different solid tumors. Olaparib (AZD2281, KU-0059436) is a potent Polyadenosine 5'diphosphoribose [poly (ADP ribose] polymerisation (PARP) inhibitor (PARP-1,-2 and-3) with proven antitumoral activity in homologous recombination deficient (HRD) tumors. Olaparib is being developed as an oral therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy and other anti-cancer agents. The combination of PM01183 and Olaparib has shown synergistic activity in cell-lines independent of HRD status.

Trial design

This first-in-human phase I-II study evaluates the safety and tolerability of PM1183 in combination with short course of Olaparib through a 3 + 3 dose escalation design Selection of patients: Phase-I patients with advanced or metastatic solid tumors without established standard therapeutic alternatives. Phase-II expansion cohort: platinum-resistant ovarian cancer patients (epithelial non-mucinous), triple negative breast and endometrial cancer patients. For patients included in the phase-II part of the study, evidence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 will be required. Primary endpoints are Phase-I: safety (MTD, DLT and RP2D); Phase-II: overall response rate. Secondary enpoints: Progression Free survival, Overall survival, PK and pharmacodynamic profiles, safety profile. Additional translational research to analyze predictive factors to further select potential candidates will be explored. The trial is in progress; 13 of up to 48 planned pts in the phase-I part have been recruited at the end of April 2016 (enrollment started Nov 2015).

Clinical trial identification


Legal entity responsible for the study



Pharmamar, AstraZeneca


A.M. Poveda: Roche, AstraZeneca, Pharmamar, Clovis Advisor. A. Oaknin: Roche, AstraZeneca, Clovis Advisor. A. Soto: Pharmamar employee and market share owner. All other authors have declared no conflicts of interest.